<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357486</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/22</org_study_id>
    <nct_id>NCT01357486</nct_id>
  </id_info>
  <brief_title>Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis</brief_title>
  <acronym>PRODIGE 21</acronym>
  <official_title>Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of Hepatocellular Carcinoma (HCC) is currently increasing in Europe and in
      France and about 2 / 3 of patients, are not eligible for curative treatment at the time of
      diagnosis. The palliative management of patients with advanced and symptomatic disease is
      complex and requires treatment combining anti-tumor activity and safety in patients with
      impaired liver functions. Sorafenib is the standard of care in a palliative setting, but the
      benefit of sorafenib in patient with altered liver function is uncertain. The aim of this
      trial is to study the interest of sorafenib in patients with HCC and impaired liver function
      compared to pravastatin (a drug with anti-tumoral activity in HCC) or to the combination
      sorafenib/pravastatin or to best supportive care (usually used in these patients).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of Hepatocellular Carcinoma (HCC) is currently increasing in Europe and in
      France. It almost always occurs on liver disease and in 80 to 90% of cases, at least in
      France, on liver with cirrhosis. If curative treatment may be proposed for some &quot;small&quot; HCC
      (transplantation, resection, percutaneous destruction), about 2 / 3 of patients, which
      represents nearly 4,000 new cases per year in France, are not eligible for such treatment.
      The palliative management of patients with advanced and symptomatic disease is complex and
      requires treatment combining anti-tumor activity and safety in patients with impaired liver
      functions. Indeed, in most cases the palliative treatment of HCC is applied to patients with
      altered liver function (stage B of the Child-Pugh classification).

      To date, the proposed treatment in France for such patients is based on best supportive care.

      The objective of this study is to assess the interest in this situation of 2 molecules -
      taken alone or in combination:

        -  Sorafenib, the reference in the palliative treatment of advanced hepatocellular
           carcinoma (Stage C of the BCLC classification). Yet the safety and efficacy of sorafenib
           in patients with altered liver function (CHILD B) are not clearly defined and its use
           remains discouraged by French recommendations in these patients.

        -  Pravastatin whose interest in the palliative treatment of HCC was suggested by several
           phase II studies with a good safety profile in cirrhotic patients.

      In this French multicenter open randomized study, 160 patients will be included in 4 arms
      (40/arms): sorafenib, pravastatin, pravastatin + sorafenib, and supportive care.

      The aim of this phase II multicenter study is to select the two best arms for further Phase
      III study in order to identify a reference treatment in this palliative situation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2011</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">April 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to radiologic progression</measure>
    <time_frame>Every 4 weeks (CT-scan or MRI) until progression of HCC or date of last news (for patients alive or dead without progression)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>End of the study (estimated date August 2012)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without progression</measure>
    <time_frame>Every 4 weeks (CT-scan or MRI) until progression of HCC or date of last news (for patients alive or dead without progression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>every 4 weeks (CT-scan or MRI) until clinical or radiological progression of HCC or date of last news (for patients alive or dead without progression)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate at four months</measure>
    <time_frame>Radiological evaluation at 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and description of AE for toxicity and SAE</measure>
    <time_frame>Clinical evaluation every month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Clinical evaluation every month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>CHILD B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving sorafenib 400 mg - twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving pravastatin 40 mg - once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients receiving best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>patients receiving sorafenib 400 mg - twice a day</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>patients receiving pravastatin 40 mg - once a day</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib + Pravastatin</intervention_name>
    <description>patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients receiving best supportive care</intervention_name>
    <description>palliative management</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Male and female subjects &gt; 18 years age

        - Hepatocellular carcinoma histologically diagnosed or in case of inability to perform a
        histology by non invasive radiological criteria in presence of known cirrhosis: (i) Hepatic
        lesion measuring between 1 and 2 cm in diameter : CT-scan + MRI (eventually an Ultrasound
        contrast) : HCC diagnosed with contrast uptake in the arterial phase and rapid wash out in
        the venous /late phase on two imaging techniques.

        (ii)Hepatic lesion with a diameter &gt; 2 cm : CT-scan or MRI +alpha fetoprotein : HCC
        diagnosed with contrast uptake in the arterial phase and a rapid wash out in the venous
        /late phase or a alpha fetoprotein &gt; 200µg/L

          -  Patient not eligible for curative treatment (transplantation, resection, destruction
             or percutaneous chemo-embolization) or HCC still evolving after failure of a specific
             treatment

          -  Score CHILD B

          -  ECOG performance status 0/1/2

          -  Score BCLC B or C

          -  Adequate haematologic function with haemoglobin &gt; 8 g/dl, platelet count &gt; 50000x
             109/L, absolute neutrophil count &gt; 1000 / mm3

          -  Creatinine &lt; 2 times the upper limit of normal

          -  Written informed consent

        Exclusion Criteria:

          -  Any condition that is unstable or could jeopardize the safety of the subject and their
             compliance in the study

          -  Pregnancy

          -  Myocardial infarction less than 6 months, uncontrolled hypertension, congestive heart
             failure(NYHA class &gt; 2) , anti- arrhythmic treatment other than beta-blockers or
             digoxin

          -  Digestive bleeding within 30 days before inclusion

          -  Hepatic transplantation

          -  Patients receiving or having received a statine for less than 6 months before HCC
             diagnostic

          -  Prior use of sorafenib

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Previous or concurrent cancer, except cervical carcinoma in situ, treated basal cell
             carcinoma, superficial bladder tumor. Any cancer curatively treated &gt; 5 years prior to
             entry is permitted

          -  Known or suspected history of allergy to sorafenib or pravastatin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Frédéric BLANC, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH d'Abbeville</name>
      <address>
        <city>Abbeville</city>
        <zip>80142</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pays d'Aix</name>
      <address>
        <city>Aix-en-provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Auxerre</name>
      <address>
        <city>Auxerre</city>
        <zip>89011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP- Hôpital Jean-Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Duchenne</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Béziers</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Départemental Vendée</name>
      <address>
        <city>La Roche-sur-yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont-de-marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Hôpital de l'Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans - Hôpital La Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hôpital du Haut Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint-Malo</name>
      <address>
        <city>Saint Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau CLCC Nantes Atlantique</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Gaston Ramon</name>
      <address>
        <city>Sens</city>
        <zip>89100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte contre le Cancer Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg Hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg, Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </reference>
  <reference>
    <citation>Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007 Jan;46(1):69-76. Epub 2006 Jul 28.</citation>
    <PMID>16935385</PMID>
  </reference>
  <reference>
    <citation>Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001 Apr 6;84(7):886-91.</citation>
    <PMID>11286466</PMID>
  </reference>
  <reference>
    <citation>Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, Nader M, Schusdziarra V. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation. Hepatogastroenterology. 2004 Jul-Aug;51(58):1099-103.</citation>
    <PMID>15239254</PMID>
  </reference>
  <reference>
    <citation>Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006 Apr 17;97(8A):77C-81C. Epub 2006 Feb 3.</citation>
    <PMID>16581333</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.</citation>
    <PMID>18477802</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>CHILD B</keyword>
  <keyword>palliative management</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Pravastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

